CMS Medicare Director David Brooks acknowledged concerns about the impact that Medicare negotiated prices for Part B drugs would have on providers, but said Congress must fix them.
CMS Medicare Director David Brooks acknowledged concerns about the impact that Medicare negotiated prices for Part B drugs would have on providers, but said Congress must fix them.